A post by @FirstSquawk on X.

Pulse Biosciences reported that 86% of patients achieved more than 50% thyroid nodule volume reduction at six months, with median nodule volume reduction reaching 72%. The results also showed significant quality-of-life improvements and no serious adverse events disclosed in the initial update. The strong efficacy signals matter because they support the company’s thyroid treatment program and could strengthen its position in a competitive benign-thyroid intervention market. Investors will watch for the full dataset, including safety details and duration of response, along with any regulatory or trial-next-step guidance from management.